SCHEDULE: Cormorant Asset Management Discloses BioAge Labs Stake

Cormorant Asset Management, LP and Bihua Chen have reported a beneficial ownership of 6.51% in BioAge Labs, Inc. common stock as of March 31, 2026.

Summary

• Cormorant Asset Management, LP, acting as an investment adviser for certain funds, and Bihua Chen have jointly filed a Schedule 13G, indicating their beneficial ownership of BioAge Labs, Inc. common stock.
• As of March 31, 2026, the reporting persons collectively beneficially own 2,890,605 shares of BioAge Labs, Inc. common stock.
• This holding represents 6.51% of the class of securities outstanding.
• The filing is an amendment (Amendment No. 3) to a previous Schedule 13G filing.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a standard disclosure of beneficial ownership and does not provide new operational or financial performance data for BioAge Labs, Inc.

Positives

• Cormorant Asset Management, LP and Bihua Chen have disclosed a significant stake in BioAge Labs, Inc., potentially indicating confidence in the company's future prospects.
• The filing confirms a substantial beneficial ownership of 2,890,605 shares, representing 6.51% of the outstanding common stock.

Risks

• The filing does not contain specific risk factors related to BioAge Labs, Inc. itself, but any investment carries inherent market risks.
• As a Schedule 13G filing, it primarily reports ownership and does not delve into operational or strategic risks of the company.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from BioAge Labs, Inc. It is a disclosure of beneficial ownership by Cormorant Asset Management, LP and Bihua Chen.

Management Comments

• The filing should not be construed as an admission that any of the reporting persons are, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to disclose their holdings. This filing indicates Cormorant Asset Management, LP's continued or new interest in BioAge Labs, Inc., a biotechnology company, within a sector often characterized by significant investment and potential for growth or volatility.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an investment firm like Cormorant Asset Management, LP can be viewed positively by other shareholders, potentially indicating institutional confidence. However, it also means a larger portion of the company is held by a single entity, which could influence future corporate actions.
• Management of BioAge Labs, Inc.: The reporting persons' certification that the shares are not held to influence control suggests a passive investment, but significant holdings can still lead to engagement on governance matters.
• Potential Investors: This filing provides transparency on major shareholders, which is a key piece of information for potential new investors evaluating the company's ownership structure.

Next Steps

• Cormorant Asset Management, LP and Bihua Chen will continue to hold their shares in BioAge Labs, Inc. and will file amendments to this Schedule 13G as required by SEC regulations if their beneficial ownership changes significantly.

Key Dates

Keywords

BioAge Labs, Cormorant Asset Management, Schedule 13G, Beneficial Ownership, SEC Filing, Investment Adviser, Common Stock, Securities